The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03D | Other systemic drugs for obstructive airway diseases | |
| 4 | R03DC | Leukotriene receptor antagonists | |
| 5 | R03DC01 | Zafirlukast |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 40 mg |
| Active Ingredient | Description | |
|---|---|---|
| Zafirlukast |
Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slowreacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ACCOLATE Coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
